OKYO Pharma (OKYO) Assets Average (2022 - 2026)
OKYO Pharma (OKYO) posted quarterly Assets Average of $12.8 million for Q1 2026, up 293.78% year-over-year from $3.3 million in Q1 2025, and up 207.89% quarter-over-quarter from $4.2 million in Q3 2025.
OKYO Pharma (OKYO) Assets Average (2022 - 2026) Analysis & Trends
OKYO Pharma (OKYO) has reported Assets Average for 5 consecutive years, with $12.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Assets Average rose 293.78% year-over-year to $12.8 million; the TTM figure through Mar 2026 stood at $12.8 million (up 293.78% YoY), while the FY2026 annual figure was $12.3 million, up 372.42% from the prior year.
- Assets Average improved to $12.8 million in Q1 2026 per OKYO's latest filing, from $4.2 million in the prior quarter.
- Across five years, Assets Average topped out at $12.8 million in Q1 2026 and bottomed at $2.0 million in Q1 2024.
- Historically, Assets Average has averaged $4.8 million across 5 years, with a median of $4.0 million in 2023.
- Annual changes were most pronounced in 2024 — Assets Average tumbled 58.77% — and 2026, when it jumped 293.78%.
- OKYO Pharma's Assets Average stood at $5.7 million in 2022, then tumbled by 33.45% to $3.8 million in 2023, then sank by 42.36% to $2.2 million in 2024, then jumped by 90.41% to $4.2 million in 2025, then soared by 207.89% to $12.8 million in 2026.
- Business Quant data shows OKYO's Assets Average at $12.8 million in Q1 2026, $4.2 million in Q3 2025, and $3.3 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 5.34 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 2.09 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.82 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 25.27 Bn |
| 10 | OKYO Pharma | 1.47 Bn | 1.47 Bn | - | 12.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 12.81 Mn |
| Sep 30, 2025 | 4.16 Mn |
| Mar 31, 2025 | 3.25 Mn |
| Sep 30, 2024 | 2.19 Mn |
| Mar 31, 2024 | 1.96 Mn |
| Sep 30, 2023 | 3.79 Mn |
| Mar 31, 2023 | 4.75 Mn |
| Mar 31, 2022 | 5.70 Mn |